Scientists identify new genetic drivers of cancer

February 05, 2020

The discovery of genetic drivers of cancer can have critical implications for the diagnosis and treatment of cancer patients, yet genome analysis has focused primarily on only 1-2% of the whole genome - the part that contains the code for making proteins. What about the rest? Does it also play a role in driving the disease?

As part of the Pan-Cancer project, scientists have analysed whole-genome sequencing data. To do this, the scientists had to develop new statistical methods suitable for analysing the non-coding genome.

Joachim Weischenfeldt - now a group leader at the Biotech Research & Innovation Centre at the University of Copenhagen, and Rigshospitalet, Copenhagen - was a postdoc in the Genome Biology Unit at EMBL Heidelberg at the time of the research. He explains the rationale for the investigation: "Decades of work has been focused on identifying the consequences of changes in the protein-coding part of the genome. Many cancers have no important mutations in the protein-coding part, but something is driving the cancer. By inference, we suspect the non-coding part is playing an important role in these unexplained cases."

The analysis focused on identifying driver point mutations - mutations that affect only one or very few letters of the DNA code - and structural variants, or rearrangements, in the non-coding regions of the genome. In addition to identifying new drivers, the analysis confirmed some previously reported drivers and, importantly, invalidated others. It also identified novel putative driver rearrangements near genes called the AKR1C genes. This correlated with increased gene expression across lung and liver cancers.

Mutations and structural variants driving cancer were found to be less frequent in non-coding genes and sequences than in the protein-coding part of the genome, but this could partly be due to the relatively small number of patient datasets available to analyse for some tumour types. "We probably need an order of magnitude more genomes to really have a comprehensive understanding of all the mutations that drive cancer, and the complex mechanisms by which they form," says Weischenfeldt. "As cancer is a disease of the genome, we ultimately want to be able to explain as many cancers as possible using genetics."

Thanks in large part to the work carried out during the Pan-Cancer project, about 95% of the cancers studied could be explained genetically by a driver mutation. One of the key outputs of the project is a catalogue that clinicians and researchers can use to look up specific tumour types and identify the drivers of the disease.

The Pan-Cancer project

The Pan-Cancer Analysis of Whole Genomes project is a collaboration involving more than 1300 scientists and clinicians from 37 countries. It involved analysis of more than 2600 genomes of 38 different tumour types, creating a huge resource of primary cancer genomes. This was the starting point for 16 working groups to study multiple aspects of cancer development, causation, progression, and classification.

European Molecular Biology Laboratory

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to